A post hoc analysis of 4 phase 3 trials found that nemolizumab-ilto, an interleukin-31 inhibitor, reduced itch and sleep disturbance as early as day 2 in patients with moderate-to-severe atopic dermatitis and prurigo nodularis, with greater and sustained benefit versus placebo through week 16, suggesting IL-31 inhibition offers rapid, durable pruritus control in both conditions.

Source: Journal of the European Academy of Dermatology & Venereology